MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: In and out of fashion

Pharmacogenomics

Volumn 10, Issue 5, 2009, Pages 711-713

  Löscher, Wolfgang ^a   Delanty, Norman ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBON 11; GLYCOPROTEIN P; MESSENGER RNA; PHENOBARBITAL; TARIQUIDAR; VERAPAMIL;

BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG TRANSPORT; EDITORIAL; EPILEPSY; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; MDR1 GENE; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SEDATION; SIDE EFFECT; TEMPORAL LOBE EPILEPSY;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; EPILEPSY; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 66849121735     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.47     Document Type: Editorial

References (20)

1. Schmidt D, Löscher W: Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46, 858-877 (2005).
2. Löscher W, Potschka H: Drug resistance in brain diseases and the role of drug efflux transporters. Nature Rev. Neurosci. 6, 591-602 (2005).
3. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55(1), 3-29 (2003).
4. Tishler DM, Weinberg KT, Hinton DR et al.: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36, 1-6 (1995).
5. Kwan P, Brodie MJ: Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46, 224-235 (2005).
6. Sisodiya SM: Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol. 16(2), 197-201 (2003).
7. Schmidt D, Löscher W: New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 9, 47-52 (2009).
8. Siddiqui A, Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transportef gene ABCB1, N. Engl. J. Med. 348 (15), 1442-1448 (2003).
9. Löscher W, Klotz U, Zimprich F, Schmidt D: The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50, 1-23 (2009).
10. Bournissen FG, Moretti ME, Juurlink DN et al.: Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: A meta-analysis. Epilepsia 50(4), 898-903 (2008).
11. Cucullo L, Hossain M, Rapp E et al.: Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48(3), 505-516 (2007).
12. Luna-Tort6s C, Fedrowitz M, Löscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55, 1364-1375 (2008).
13. Ebid AH, Ahmed MM, Mohammed SA: Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism, perspective study. Ther. Drug Monit. 29(3), 305-312 (2007).
14. Basic S, Hajnsek S, Bozina N et al.: The influence of C3435T polymorphism. of ABCB1 gene on penetration of phenobarbital across blood-brain barrier in patients with generalized epilepsy. Seizure Eur. J. Epilepsy 17, 524-530 (2008).
15. Mosyagin I, Runge U, Schroeder HW et al.: Association of ABCB1 genetic variants 3435C>T and 2677G >T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49 (9), 1555-1561 (2008).
16. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent'polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
17. Kinirons P, McCarthy M, Doherty CP, Delanty N: Predicting dfug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 15(6), 387-392 (2006).
18. Remy S, Beck H: Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129(Pt 1), 18-35 (2006).
19. Langer O, Bauer M, Hammers A et al.: Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R- [C] verapamil. Ipilepsia 48, 1774-1784 (2007).
20. Bankstahl J P, Kuntner C, Abrahim A et al.: Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with R)-11C-verapamil and PET. J Nucl. Med. 49(8), 1328-1335 (2008).